drugset / Trial / NCT01810185

Low Dose Naltrexone in Symptomatic Inflammatory Bowel Disease

NCT01810185

Phase 2 Withdrawn Santa Barbara Cottage Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The investigators will be looking at the efficacy of the use of once daily use of low dose naltrexone (4.5mg) in subjects with symptomatic inflammatory bowel disease.

Timeline

Start
2013-03
Primary completion
2014-03
Completion
2014-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Naltrexone Small molecule 4.5 mg Oral